19-11033783-C-T

Variant summary

Our verdict is Benign. The variant received -7 ACMG points: 0P and 7B. BP4_ModerateBP6BS1

The NM_001387283.1(SMARCA4):​c.3791C>T​(p.Thr1264Met) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000628 in 779,866 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 13/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. T1264A) has been classified as Uncertain significance.

Frequency

Genomes: 𝑓 0.000046 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000067 ( 1 hom. )

Consequence

SMARCA4
NM_001387283.1 missense

Scores

10
8

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:3B:4

Conservation

PhyloP100: 2.76

Publications

4 publications found
Variant links:
Genes affected
SMARCA4 (HGNC:11100): (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4) The protein encoded by this gene is a member of the SWI/SNF family of proteins and is similar to the brahma protein of Drosophila. Members of this family have helicase and ATPase activities and are thought to regulate transcription of certain genes by altering the chromatin structure around those genes. The encoded protein is part of the large ATP-dependent chromatin remodeling complex SNF/SWI, which is required for transcriptional activation of genes normally repressed by chromatin. In addition, this protein can bind BRCA1, as well as regulate the expression of the tumorigenic protein CD44. Mutations in this gene cause rhabdoid tumor predisposition syndrome type 2. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2012]
SMARCA4 Gene-Disease associations (from GenCC):
  • Coffin-Siris syndrome
    Inheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet, Illumina
  • intellectual disability, autosomal dominant 16
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae), Ambry Genetics
  • rhabdoid tumor predisposition syndrome 2
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, ClinGen, Genomics England PanelApp, Labcorp Genetics (formerly Invitae), G2P
  • uterine corpus sarcoma
    Inheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
  • familial rhabdoid tumor
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • hereditary nonpolyposis colon cancer
    Inheritance: AD Classification: LIMITED Submitted by: ClinGen

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -7 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.11120939).
BP6
Variant 19-11033783-C-T is Benign according to our data. Variant chr19-11033783-C-T is described in ClinVar as Conflicting_classifications_of_pathogenicity. ClinVar VariationId is 408620.
BS1
Variant frequency is greater than expected in population eas. GnomAd4 allele frequency = 0.000046 (7/152172) while in subpopulation EAS AF = 0.000579 (3/5180). AF 95% confidence interval is 0.000157. There are 0 homozygotes in GnomAd4. There are 3 alleles in the male GnomAd4 subpopulation. Median coverage is 33. This position passed quality control check.

Variant Effect in Transcripts

ACMG analysis was done for transcript: NM_001387283.1. You can select a different transcript below to see updated ACMG assignments.

RefSeq Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
SMARCA4
NM_001387283.1
MANE Plus Clinical
c.3791C>Tp.Thr1264Met
missense
Exon 27 of 36NP_001374212.1
SMARCA4
NM_003072.5
MANE Select
c.3791C>Tp.Thr1264Met
missense
Exon 27 of 35NP_003063.2
SMARCA4
NM_001128849.3
c.3791C>Tp.Thr1264Met
missense
Exon 27 of 36NP_001122321.1

Ensembl Transcripts

Selected
GeneTranscriptTagsHGVScHGVSpEffectExon RankProteinUniProt
SMARCA4
ENST00000646693.2
MANE Plus Clinical
c.3791C>Tp.Thr1264Met
missense
Exon 27 of 36ENSP00000495368.1
SMARCA4
ENST00000344626.10
TSL:1 MANE Select
c.3791C>Tp.Thr1264Met
missense
Exon 27 of 35ENSP00000343896.4
SMARCA4
ENST00000643995.1
c.3203C>Tp.Thr1068Met
missense
Exon 24 of 32ENSP00000496004.1

Frequencies

GnomAD3 genomes
AF:
0.0000460
AC:
7
AN:
152172
Hom.:
0
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.0000654
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.000579
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000294
Gnomad OTH
AF:
0.000478
GnomAD2 exomes
AF:
0.0000610
AC:
15
AN:
245890
AF XY:
0.0000372
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.0000290
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.000384
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000275
Gnomad OTH exome
AF:
0.000330
GnomAD4 exome
AF:
0.0000669
AC:
42
AN:
627694
Hom.:
1
Cov.:
0
AF XY:
0.0000526
AC XY:
18
AN XY:
341980
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
17700
American (AMR)
AF:
0.0000457
AC:
2
AN:
43734
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
20988
East Asian (EAS)
AF:
0.000111
AC:
4
AN:
36070
South Asian (SAS)
AF:
0.00
AC:
0
AN:
69804
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
51898
Middle Eastern (MID)
AF:
0.000241
AC:
1
AN:
4150
European-Non Finnish (NFE)
AF:
0.0000228
AC:
8
AN:
350270
Other (OTH)
AF:
0.000816
AC:
27
AN:
33080
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.486
Heterozygous variant carriers
0
4
8
12
16
20
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0000460
AC:
7
AN:
152172
Hom.:
0
Cov.:
33
AF XY:
0.0000404
AC XY:
3
AN XY:
74348
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
41446
American (AMR)
AF:
0.0000654
AC:
1
AN:
15288
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3470
East Asian (EAS)
AF:
0.000579
AC:
3
AN:
5180
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4836
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10608
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
316
European-Non Finnish (NFE)
AF:
0.0000294
AC:
2
AN:
68022
Other (OTH)
AF:
0.000478
AC:
1
AN:
2094
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.504
Heterozygous variant carriers
0
1
2
2
3
4
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.000169
Hom.:
0
Bravo
AF:
0.0000378
ExAC
AF:
0.0000412
AC:
5
Asia WGS
AF:
0.00231
AC:
8
AN:
3478
EpiCase
AF:
0.0000545
EpiControl
AF:
0.00

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:3Benign:4
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

Intellectual disability, autosomal dominant 16 Uncertain:1Benign:1
Feb 05, 2024
Revvity Omics, Revvity
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Jul 15, 2021
Genome-Nilou Lab
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Hereditary cancer-predisposing syndrome Benign:2
Nov 12, 2020
Sema4, Sema4
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:curation

Oct 15, 2020
Ambry Genetics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.

not provided Uncertain:1
Jul 08, 2016
GeneDx
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is denoted SMARCA4 c.3791C>T at the cDNA level, p.Thr1264Met (T1264M) at the protein level, and results in the change of a Threonine to a Methionine (ACG>ATG). This variant has not, to our knowledge, been published in the literature as pathogenic or benign. SMARCA4 Thr1264Met was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, suggesting it is not a common benign variant in these populations. Since Threonine and Methionine differ in polarity, charge, size or other properties, this is considered a non-conservative amino acid substitution. SMARCA4 Thr1264Met occurs at a position that is not conserved and is not located in a known functional domain (Witkowski 2014). In silico analyses are inconsistent regarding the effect this variant may have on protein structure and function. Based on currently available evidence, it is unclear whether SMARCA4 Thr1264Met is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.

SMARCA4-related disorder Uncertain:1
Jun 11, 2024
PreventionGenetics, part of Exact Sciences
Significance:Uncertain significance
Review Status:no assertion criteria provided
Collection Method:clinical testing

The SMARCA4 c.3791C>T variant is predicted to result in the amino acid substitution p.Thr1264Met. This variant was reported in an individual with left ventricular noncompaction, although additional evidence of pathogenicity was not presented (Table S5, Hirono et al. 2020. PubMed ID: 32600061). This variant is reported in 0.040% of alleles in individuals of East Asian descent in gnomAD, including one homozygous individual. It has conflicting interpretations of likely benign and uncertain significance in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/variation/408620/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence.

Rhabdoid tumor predisposition syndrome 2 Benign:1
Jan 31, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Computational scores

Source: dbNSFP v4.9

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.091
BayesDel_addAF
Benign
-0.18
T
BayesDel_noAF
Benign
-0.17
CADD
Pathogenic
27
DANN
Uncertain
0.99
DEOGEN2
Uncertain
0.46
T
Eigen
Uncertain
0.22
Eigen_PC
Uncertain
0.33
FATHMM_MKL
Uncertain
0.92
D
LIST_S2
Uncertain
0.88
D
M_CAP
Benign
0.070
D
MetaRNN
Benign
0.11
T
MetaSVM
Uncertain
0.030
D
MutationAssessor
Benign
0.90
L
PhyloP100
2.8
PrimateAI
Uncertain
0.69
T
PROVEAN
Benign
-0.64
N
REVEL
Benign
0.27
Sift
Uncertain
0.016
D
Sift4G
Uncertain
0.060
T
Polyphen
0.56
P
Vest4
0.26
MutPred
0.24
Loss of glycosylation at T1264 (P = 0.0328)
MVP
0.71
MPC
1.6
ClinPred
0.043
T
GERP RS
5.2
PromoterAI
-0.047
Neutral
Varity_R
0.11
gMVP
0.55
Mutation Taster
=98/2
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs377119410; hg19: chr19-11144459; COSMIC: COSV60802766; COSMIC: COSV60802766; API